Ivabradina Farmoz (Ivabradine Hydrochloride)

• Ivabradine acts on the cardiac If‑channel to lower heart rate, providing therapeutic benefit in angina and heart failure.
• Chronic stable angina: decreases frequency of angina attacks and improves exercise tolerance.
• Heart failure with reduced ejection fraction: lowers heart rate, which can improve symptoms and reduce hospitalization risk.
• Ischemic heart disease (symptomatic): helps control heart rate and relieve chest discomfort.

• Ivabradine selectively binds to the funny (If) channels in the sinoatrial node, inhibiting the inward mixed Na⁺/K⁺ current that drives spontaneous depolarization. By reducing this pacemaker current, the drug slows the sinus rate without affecting myocardial contractility, ventricular repolarization, or blood pressure, resulting in a heart‑rate‑lowering effect that improves myocardial oxygen balance.

Ivabradina Farmoz may be associated with several adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects

• Visual disturbances (phosphenes): transient luminous phenomena often reported as bright spots.
• Bradycardia: heart rate falls below the prescribed range, potentially causing fatigue.
• Headache: mild to moderate intensity, commonly occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects

• Severe bradycardia leading to syncope or fainting episodes.
• Atrial fibrillation: irregular rapid heart rhythm requiring medical attention.
• Symptomatic hypotension: marked drop in blood pressure causing weakness.
• Visual impairment (retinal): rare cases of blurred vision or visual field changes.

Before prescribing Ivabradina Farmoz, clinicians should consider several safety measures.

• Cardiovascular assessment: evaluate baseline heart rate and rhythm before initiating therapy.
• Monitor heart rate: regularly check pulse to ensure it remains above the recommended minimum.
• Concomitant bradycardic agents: avoid or adjust dose when used with beta‑blockers, digoxin, or non‑dihydropyridine calcium‑channel blockers.
• Hepatic impairment: use with caution in patients with moderate to severe liver dysfunction.
• CYP3A4 inhibitors: avoid strong inhibitors such as ketoconazole or clarithromycin.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Ivabradina Farmoz can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels and cause excessive bradycardia.
• Co‑administration with other heart‑rate‑lowering drugs (beta‑blockers, digoxin, non‑dihydropyridine calcium‑channel blockers): risk of severe bradycardia and atrioventricular block.
• Quinidine: can potentiate ivabradine effects and lead to marked heart‑rate reduction.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (diltiazem, verapamil): may require dose adjustment and close monitoring of heart rate.
• CYP3A4 inducers (rifampicin, carbamazepine, phenytoin): may reduce ivabradine exposure and diminish efficacy.
• Diuretics causing electrolyte imbalance: monitor electrolytes as shifts may affect cardiac conduction.